Erythrocytosis
Conditions
Interventions
Gold Standard:Lack of GS or RS, such as the 51Cr marker method, etc.
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
15 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 15 to 85 years old (The median age at diagnosis of polycythemia vera is about 60 years old, and the incidence of this disease gradually increases with age. The most patients are over 60-80 years old with polycythemia vera; 2. More than two times a week, male red blood cell count > 6*10^12/L and hemoglobin concentration>165 g/L or female red blood cell count > 5.5*10^12/L and hemoglobin concentration>160 g/L; The?subject have definite cause of disease and sign the informed consent. 3. Etiological diagnosis is carried out according to the latest international standards: (1) Polycythemia Vera GroupAbnormal bone marrow examination, JAK2 gene mutation positive, low or significantly reduced EPO levels; (2) None Polycythemia Vera GroupIncluding secondary polycythemia and relative polycythemia: 1) Secondary polycythemia in obstructive sleep disorder?Sleep apnea confirmed by sleep monitoring, high or significantly higher EPO, decreased saturation of arterial blood oxygen (SAO2); 2) Secondary polycythemia in the increase of tumor or renal derived EPO secretionAbnormal liver and kidney function examination,related focus comfirmed?by imaging or pathological findings; 3) Relative polycythemia caused by adrenocortical insufficiency; The total cortisol base value is less than 3 mu g/dl,normal EPO level.
Exclusion criteria
Exclusion criteria: 1. Severe cardiopulmonary disease; 2. In use of hydroxyurea and other myelosuppressive drugs for treatement; 3. Smoking within 24 hours before test; 4. Severe passive smoking or in other environment seriously polluted by high concentration of CO within 24 hours before test; 5. Incapable of self completing exhalation; 6. In process of other clinical trials involving drugs or medical devices within 3 months before test; 7. The researchers think it is not appropriate for him or her to take part in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Erythrocyte lifespan; | — |
Secondary
| Measure | Time frame |
|---|---|
| Erythropoietin (EPO);Reticulocyte percentage(Ret%); | — |
Countries
China
Contacts
Public ContactZonghong Shao
Department of Hematology, Tianjin Medical University General Hospital
Outcome results
None listed